All News

In Europe, the authors of this new study suggest, some patent barriers may be more illusory than real.

New research could make it easier to find out which patients are mostly likely to go on to develop multiple myeloma. The findings could have implications for therapeutic interventions.

The FDA announced today it will grant emergency use authorization to Gilead Sciences' remdesivir, a drug that showed early promise in treating coronavirus disease 2019 (COVID-19).

In recent years, targeted cancer therapies have increased in use. These individualized treatments are based on the genetic makeup of a patient's disease.

There is a 15% to 20% greater chance of death in the 90 days following a hospitalization for heart failure among patients with Medicare compared with the general population. Social determinants of health (SDOH) are an influencing factor of this rate.

Those who lived alone had more risk for respiratory disease hospitalization compared with those who did not, the study authors said.

Florida Cancer Specialists will pay $100 million as a criminal penalty for antitrust violations; CMS will exclude spending associated with the coronavirus disease 2019 pandemic from accountable care organization (ACO) performance calculations; the Department of Veterans Affairs orders $300,000 worth of body bags.

Chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) is rare, making it difficult to differentiate from other types of lymphoma. A new study helps explain key unique traits.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

A new review article finds patients who suffer from psoriatic arthritis (PsA) face a higher risk of type 2 diabetes (T2D), though the exact reasons for the linkage are not yet clear.

Overall, biosimilar rituximab was used in more than 50% of patients, both as first-line therapy, second line or later.

In a commentary published in Multiple Sclerosis and Related Disorders, experts addressed common concerns individuals with multiple sclerosis (MS) might have when it comes to the coronavirus disease 2019 (COVID-19) pandemic and the use of disease-modifying therapies (DMTs).

According to 2015 CDC data, current viral suppression rates from antiretroviral therapy (ART) leave room for improvement among both HIV-positive individuals who are aware of their disease status and those receiving care, at 40.0% and 81.5%, respectively.

Incorporation of remote electrical neuromodulation into usual care reduced migraineurs’ use of acute migraine medication, potentially decreasing the risk of medication overuse headache, according to a study published in Frontiers in Neurology.

Outcomes were worse for patients with multiple myeloma (MM) and extramedullary disease, and the authors said their findings indicate that evaluation of extramedullary response using imaging is needed in this group.

Compared with patients who have just sleep apnea syndrome (SAS), those with both SAS and restless leg syndrome were shown to exhibit a higher degree of insomnia-specific psychological symptoms, which may indicate the benefit of cognitive behavioral therapy in these populations, according to study findings.

Doctors are reporting challenges when it comes to accessing electronic medical record (EMR) data for patients with coronavirus disease 2019 (COVID-19); Los Angeles will be the first US city to test all residents, regardless of symptom presence; Supplemental Nutrition Assistance Program (SNAP) enrollees are struggling with social distancing guidelines.

The risk of both heart attack and stroke increases 2- to 3-fold among individuals with comorbid diabetes and cardiovascular issues; however, recent study results show improved odds of both not occurring, as well as less of a risk of hospitalization for heart failure or lower extremity amputation.

A new pooled analysis of rituximab/bendamustine and rituximab/cytarabine in transplant-eligible patients with mantle cell lymphoma (MCL) finds it leads to durable positive results in most patients.

Investigators still have a lot to learn about the links among psoriatic arthritis, inflammation, and depression, but a growing body of evidence suggests significant interplay.

Preliminary data from a National Institutes of Health (NIH) clinical trial show Gilead Sciences' remdesivir accelerates recovery in patients with advanced coronavirus disease 2019 (COVID-19) infections.

In an opinion article published in JAMA Neurology, researchers discuss how the coronavirus disease 2019 (COVID-19) pandemic has transformed neurologic care more than any other crisis in modern history.

Racial disparities are a leading factor in the impact of pollution on concentrated populations; Pfizer could begin initial testing of its coronavirus vaccine as soon as next week; study results of a new liquid biopsy point to the ability to detect cancers before they have spread.

Preexposure prophylaxis (PrEP) was first approved by the FDA in 2012, but only for use among adults. An indication was added in 2018 for its use among adolescents.

Retinal displacement may be more severe and occurs more frequently in patients who undergo pars plana vitrectomy as opposed to pneumatic retinopexy for rhegmatogenous retinal detachment repair, according to a study published in JAMA Ophthalmology.

Recent study results show that patients with cancer who develop coronavirus disease 2019 (COVID-19) are far more likely to die than those who develop COVID-10 but do not have cancer. Patients being treated with immunotherapy appear to be at particularly high risk.

Compared with patients with low stress, patients with chronic obstructive pulmonary disease (COPD) and high stress had doubled odds of using acute care services, a new study found.

In new data from the phase 3 EMBRACA trial presented yesterday at the American Association for Cancer Research annual meeting, researchers found that PARP inhibitor talazoparib exhibited no statistically significant benefit in the secondary end point of overall survival in patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.